EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies

EyePoint Pharmaceuticals announced positive six-month results from the Phase 2 VERONA trial of DURAVYU (vorolanib) for wet age-related macular degeneration (AMD)6.

DURAVYU is a novel pan-VEGF receptor inhibitor delivered via a single intravitreal injection, potentially offering a new mechanism of action for treating VEGF-mediated retinal diseases6 2.

The Phase 2 trial demonstrated clinically meaningful efficacy with stable visual acuity and central subfield thickness (CST), along with a favorable safety profile6.

DURAVYU showed an impressive treatment burden reduction of approximately 88% six months after treatment, with over 80% of patients requiring no supplemental anti-VEGF injections or only one6.

EyePoint's stock price has been volatile, with a significant surge of about 261% following the announcement of positive Phase 2 results in December 20238.

As of February 7, 2025, EyePoint's stock price closed at $6.50, showing a 3.76% increase for the year 2025 but a significant drop from its 2024 performance5.

DURAVYU is currently being evaluated in two ongoing global Phase 3 clinical trials, LUGANO and LUCIA, for wet AMD6.

The development of DURAVYU represents a potential challenge to established anti-VEGF therapies like Eylea, which have dominated the market for wet AMD treatment4.